{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T07:14:03Z","timestamp":1696662843719},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,12,26]],"date-time":"2014-12-26T00:00:00Z","timestamp":1419552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostic Cytopathology"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>High\u2010risk HPV (hrHPV) testing is now <jats:italic>considered<\/jats:italic> standard of care in the detection and management of cervical high\u2010grade squamous intraepithelial lesions (HSIL\/CIN 2\u20133) and their precursors. Recently, there has been concern in the scientific literature and lay media about the lack of data regarding the false\u2010negative rate (FNR) of HPV testing on SurePath<jats:sup>TM<\/jats:sup> cytology specimens. This is a critical issue, since guidelines on the management of Pap test abnormalities rely heavily on HPV status. We undertook this study to determine whether HPV testing on SurePath<jats:sup>TM<\/jats:sup> specimens is less sensitive compared to reports in the literature for ThinPrep\u00ae.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We identified women with new diagnoses of CIN 2, CIN 3, and squamous cell carcinoma (SCC) on biopsy or excision in 2009\u20132013. For each patient, we recorded all SurePath<jats:sup>TM<\/jats:sup> cytology and hrHPV HC2 (high\u2010risk HPV Hybrid Capture 2) test results from within 5 years prior to histologic diagnosis. Using the histologic diagnosis as the gold standard, we calculated the sensitivities of cytology and hrHPV HC2 tests for the detection of CIN 2, 3, and SCC. Our findings are based only on women who underwent biopsy or excision after having an abnormal cytology and\/or positive HPV result.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In our cohort, the sensitivity of testing in the 5 years prior to histologic diagnosis of CIN 2, 3, and SCC (combined as a single group) is 98.4% for SurePath<jats:sup>TM<\/jats:sup> cytology, 95.3% for hrHPV HC2, and 100% if both tests are used together. No conclusion can be drawn regarding testing for SCC alone, because there was only one case of SCC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results show that the false\u2010negative rate of hrHPV HC2 testing on SurePath<jats:sup>TM<\/jats:sup> specimens for the detection of CIN 2 and CIN 3 is low and comparable to that of ThinPrep\u00ae specimens. Diagn. Cytopathol. 2015;43:381\u2013387. \u00a9 2014 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/dc.23243","type":"journal-article","created":{"date-parts":[[2014,12,27]],"date-time":"2014-12-27T04:47:20Z","timestamp":1419655640000},"page":"381-387","source":"Crossref","is-referenced-by-count":5,"title":["Sensitivity of high\u2010risk <scp>HPV<\/scp><scp>H<\/scp>ybrid <scp>C<\/scp>apture II (hrHPV HC2) test using <scp>S<\/scp>ure<scp>P<\/scp>ath<sup>TM<\/sup> specimens in the prediction of cervical high\u2010grade squamous lesions"],"prefix":"10.1002","volume":"43","author":[{"given":"Fang","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Pathology New York University School of Medicine New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Pulinthanathu","sequence":"additional","affiliation":[{"name":"Department of Pathology New York University School of Medicine New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Elgert","sequence":"additional","affiliation":[{"name":"Department of Pathology New York University School of Medicine New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Cangiarella","sequence":"additional","affiliation":[{"name":"Department of Pathology New York University School of Medicine New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aylin","family":"Simsir","sequence":"additional","affiliation":[{"name":"Department of Pathology New York University School of Medicine New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,12,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S37273"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/87.11.796"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S44258"},{"key":"e_1_2_6_5_1","unstructured":"United States preventive services task force. Screening for cervical cancer [Internet]. Available from:http:\/\/www.uspreventiveservicestaskforce.org\/uspstf11\/cervcancer\/cervcancerrs.htm#clinical. Last accessed on December 12 2014."},{"key":"e_1_2_6_6_1","unstructured":"The American society for colposcopy and cervical pathology. Cervical cancer screening recommendations [Internet].http:\/\/www.asccp.org\/Portals\/9\/docs\/pdfs\/Practice%20Management\/ASCCP_Cervical_Cancer_Screening_Recommendations.pdf#zoom=80. Last accessed on December 12 2014."},{"key":"e_1_2_6_7_1","unstructured":"POET reports College of American Pathologists. Human papilloma virus DNA testing (HPV) [Internet]. Available from:http:\/\/www.cap.org\/apps\/cap.portal?_nfpb=true&cntvwrPtlt_actionOverride=%2Fportlets%2FcontentViewer%2Fshow&cntvwrPtlt%7BactionForm.contentReference%7D=committees%2Ftechnology%2FHPV.html&_pageLabel=cntvwr. Last accessed on January 15 2014."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djg037"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.LGT200570"},{"key":"e_1_2_6_10_1","volume-title":"The Bethesda system for reporting cervical cytology: Definitions, criteria, and explanatory notes","author":"Solomon D","year":"2006"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.2307\/2685469"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22285"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.20177"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1309\/4DXEAFG2JXYF34N3"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22688"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1309\/XFUCPP6M5XUA94B8"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22425"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21664"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-013-3015-5"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2011-0609-OA"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.4.293"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1447-0756.2011.01709.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPWW6V2KGXODUI"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1309\/BFVVU29HCC5RCKY5"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22951"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000326118"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.20043"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2006.05.033"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00759-13"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11058"},{"key":"e_1_2_6_31_1","first-page":"S45","article-title":"Correlates of SurePath HPV detection","volume":"1","author":"Kerley J","year":"2012","journal-title":"JASC"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2009.00661.x"},{"key":"e_1_2_6_33_1","unstructured":"Digene Hybrid Capture II [package insert]. Gaithersburg MD USA: Digene;2008."},{"key":"e_1_2_6_34_1","first-page":"S34","article-title":"The effect on DNA recovery for high\u2010risk HPV (human papillomavirus) testing by the addition of 50% ethanol preservative to the SurePath tube after initial pap test processing","volume":"1","author":"Sweeney B","year":"2012","journal-title":"JASC"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1159\/000328554"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2011.07.024"}],"container-title":["Diagnostic Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdc.23243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdc.23243","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dc.23243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T07:59:53Z","timestamp":1696579193000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/dc.23243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,26]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1002\/dc.23243"],"URL":"https:\/\/doi.org\/10.1002\/dc.23243","archive":["Portico"],"relation":{},"ISSN":["8755-1039","1097-0339"],"issn-type":[{"value":"8755-1039","type":"print"},{"value":"1097-0339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,26]]}}}